Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis

Table 5 Subgroup analysis between the autologous/MSCs alternative therapy group and the allogeneic/MSCs additional therapy group

Outcomes	Autologous/MSCs alternative therapy				Allogeneic/MSCs additional therapy				Subgroup differences
Outcomes	Number of trials	Number of patients	RR/WMD	95% CI	Number of trials	Number of patients	RR/WMD	95% CI	p value	Heterogeneity p value (%)
1-year AR rate	1	103	0.68	0.32, 1.45	3	94	1	0.3, 3.32	0.59	0
1-year graft survival rate	1	103	0.98	0.92, 1.05	2	62	1	0.9, 1.11	0.77	0
DGF rate	1	103	0.98	0.26, 3.71	1	42	0.29	0.07, 1.22	0.22	33.7
1-year infection rate	1	103	0.63	0.42, 0.95	3	94	0.67	0.37, 1.2	0.89	0
Renal graft function postsurgery at 12 months	1	103	1.2	−9.21,11.61	3	94	−2.31	−9.7,5.08	0.59	0

MSCs mesenchymal stromal cells, AR acute rejection, DGF delay graft function, RR risk ratio, WMD weighted mean difference, CI confidence intervals

ISSN: 1757-6512